THAR Tharimmune: Utang jangka cendhak perusahaan

Tharimmune, Inc. (THAR) is developing antibodies to combat liver cancer and pruritus, targeting a niche pharmaceutical market. The company maintains flexibility through the complete outsourcing of production and testing. However, a high dependence on early-stage outcomes creates significant risks. The short-term debt structure illustrates financial stability, with 0.00 serving as the current metric value, capturing the present level of debt load.

This metric aggregates all liabilities of Tharimmune, Inc. (THAR) with a maturity of up to one year, reflecting the current liquidity and financial stability of the capital structure. For the biotechnology sector, characterized by high costs for antibody synthesis and clinical trials, historical short-term debt data serves as an indicator of the company's ability to fund R&D-intensive developments without the risk of a sudden loss of solvency.